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Effects of maternal intake of n-3 fatty acids on lipid profile and leptin 
concentration in cord blood
Anne tarafından alınan n-3 yağ asitlerinin kordon kanı lipid profiline ve leptin 
konsantrasyonuna etkisi
ÖZ
Amaç: Anne tarafından, n-3 uzun zincirli çoklu doymamış yağ 
asit (UZ-ÇDYA)’lerinin alımı, fetal gelişim ve hamilelik sonuçları 
üzerine pozitif etkilidir. Leptin, UZ-ÇDYA’larının plasentadan 
geçişinde önemli bir rol alır. Bu çalışmada, anne tarafından 
alınan UZ-ÇDYA’larının, anne ve yenidoğanın antropometrik 
ölçümlerine, kordon kanındaki yağ asitlerine ve leptin düzeylerine 
olan etkilerini araştırmayı amaçladık.
Gereç ve Yöntem: Çalışmaya 31 hamile kadın dahil edildi. 
Bunların 18’i kontrol grubuna alınırken 13’ü hamileliklerinin son 
trimesteri boyunca, n-3 UZ-ÇDYA içeren bir ilaç aldı (ilaçlı grup). 
Katılımcıların fizik muayeneleri yapıldı ve bir anket yardımıyla 
ek veriler elde edildi. Kordon kanındaki yağ asitleri ve leptin 
konsantrasyonları, sırasıyla gaz kromatograf kütle spektrometri 
(GC-MS) ve enzim bağlantılı immunosorbent test (ELISA) kiti 
kullanılarak analiz edildi.
Bulgular: Toplam n-3 ÇDYA’ların miktarı ilaç kullanımıyla 
anlamlı olarak arttı. İlaçlı grupta n-6/n-3 ÇDYA’larının oranı 
ve leptin düzeyleri daha düşüktü (P=0,052, P=0,140 sırasıyla). 
Kontrol grubunda, leptin düzeyleri ile yeni doğanların doğum 
kilosu, boyu ve baş çevresi arasında pozitif ilişki vardı. İlaç 
kullanımı, leptin konsantrasyonlarını, n-6/n-3 ÇDYA oranları ile 
pozitif ilişkili hale getirdi.
Sonuç: Günlük n-3 UZ-ÇDYA’larının alımı, anne ve yeni 
doğan sağlığının iyileşmesinde etkili olabilir.
Anahtar kelimeler : Leptin, Yağ asitleri, Kordon kanı, Yenidoğan, 
Hamilelik
Introduction
Since it is well known that intake of n-3 long chain 
polyunsaturated fatty acids (LC-PUFAs) in pregnancy 
improve gestation outcomes and newborn health, higher 
intake of n-3 LC-PUFAs during pregnancy is recommended 
[1]. Placenta has a significant impact on the transport of 
fatty acids from the maternal to the fetal circulation. Fatty 
acid composition of cord blood is changed by maternal diet 
and it reflects how much fatty acid can be taken by the fetus 
[2].
ABSTRACT
Objectives: Maternal intake of n-3 long chain polyunsaturated fatty 
acids (LC-PUFAs) has positive effects on fetal development and 
pregnancy outcomes. Leptin plays an important role in placental 
transportion of LC-PUFAs. In this study, we aimed to evaluate 
the effects of maternal n-3 LC-PUFAs intake on anthropometric 
parameters of mother and newborn, the levels of fatty acids (FAs) 
and leptin in cord blood.
Material and Methods: Thirty-one pregnant women were 
included. Eighteen were assigned to the control group and 13 
received a supplement containing n-3 LC-PUFAs during last 
trimester of gestation (supplemented group). Physical examinations 
of the participants were performed and additional data were 
collected with a questionnaire. FAs and leptin concentrations in 
cord blood samples were analyzed using gas chromatography-
mass spectrometry (GC-MS) and enzyme-linked immunosorbent 
assay (ELISA) kit respectively.
Results: A total amount of n-3 PUFAs significantly increased 
after treatment. n-6/n-3 PUFAs ratios and the leptin levels were 
lower in the supplemented group (P=0.052, P=0.140 respectively). 
There were positive correlations between leptin levels and the z 
scores for birth weight, height and head circumference of the 
newborns in the control group. The supplementation affected leptin 
concentration to be positively correlated with n-6/n-3 PUFA ratios.
Conclusion: Daily supplementation with n-3 LC-PUFAs 
might be effective to improve mother and newborn health.
Keywords: Leptin, Fatty acids, Cord blood, Newborn, Pregnancy
170 Batirel et al.
Effects of maternal intake of n-3 PUFAs Marmara Medical Journal 2017; 30: 169-176
Leptin takes a role on placental transport of nutrients 
such as fatty acids from mother to fetus [3]. Leptin levels 
in plasma are higher in pregnant mothers than that in non-
pregnant mothers [4]. It is expressed from adipose tissue of 
mother and fetus and also placenta in utero [5]. Maternal 
leptin levels in the plasma increase in the second trimester 
of pregnancy [6]. This might be caused by increased 
adipose depots and increased synthesis by the placenta. It 
is observed that umbilical leptin concentration is correlated 
with pregnancy outcomes and play a key role in fetal 
development [7-8].
Even if, it is well known that the level of fatty acids 
influence the expression and the level of leptin in non-
pregnant women [9], there is a lack of data about the impact 
of maternal n-3 LC-PUFAs intake on leptin levels during 
perinatal period [10].
For this reason, the aim of the present study was to 
evaluate the influence of n-3 LC-PUFAs supplementation 
taken by mothers during the last trimester of gestation on 
anthropometric parameters of mother and newborn and fatty 
acid composition of cord blood. As a secondary outcome, 
we also aimed to analyze the correlations of leptin levels in 
cord blood with these parameters.
Material and Methods
Participants
This study was a longitudinal study and conducted at 
Medipol University Hospital in Istanbul, Turkey between 
September 2015 and December 2016. Thirty-one expecting 
women at 22nd – 24th weeks of gestation were invited to 
participate in the study during their routine prenatal care 
visits in the hospital. The study was approved by Istanbul 
Medipol University Ethics and Research Committee. All 
women provided written informed consent to participate in 
the study and all procedures were in accordance with the 
Declaration of Helsinki. The pregnant women who gave 
preterm birth and had a history of chronic diseases and/or 
consumed omega-3 fatty acid supplements were excluded.
Supplementation
Thirteen pregnant women of 31, who accepted to take 
the supplement, were in the supplemented group and 18 
pregnant women were in the control group. The mothers 
in the supplemented group received daily a softgel (Martek 
Biosciences Corporation, Solgar, Leonia, NJ, USA) 
containing 504 mg eicosapentaenoic acid (EPA) + 378 
mg docosahexaenoic acid (DHA) from last trimester of 
gestation until delivery. The mothers in the control group 
did not take any supplement or placebo. Both groups did not 
take a dietary instruction.
Anthropometric parameters
The body weight of the mothers was measured with a 
portable scale to the the nearest 0.1 kg which was conducted 
with subjects in minimal clothes, while the height of them 
was measured using a portable measuring device to an 
accuracy of ± 0.5 cm which was fixed on the wall, with 
subjects standing straight with back, buttock, heals, and head 
against the wall. Body mass index (BMI) was calculated as 
body weight in kilograms, divided by the square of the body 
height in meters. We collected additional information data 
from the mothers by using a questionnaire.
Physical examination of the newborns was performed 
following birth. We calculated age- and sex-specific z scores 
for weight, height and head circumference of the newborns 
according to the World Health Organization (WHO) growth 
standards.
Laboratory Methods
Blood samples were collected from the umbilical cord 
after delivery. Plasma was separated in 1 hour and frozen 
immediately at -80 C0 until analysis. The samples were thawed 
on ice and vortexed vigorously before performing the assays.
In order to evaluate the effects of the supplementation 
on fatty acid status, we quantified the fatty acid composition 
in the cord blood samples using a gas chromatography-
mass spectrometry (GC-MS). Briefly, the lipids in serum 
were extracted according to Bligh and Dyer method. Fatty 
acid composition of extracted lipids was determined by 
conversion into fatty acid methyl esters (FAME). The FAME 
were separated and analyzed by a gas chromatography-mass 
spectrometry (GC-MS) (Shimadzu QP-2010, Kyoto, Japan). 
Standardization was performed using a standard mixture 
involving 37 fatty acids. Chromatograms were analysed in 
terms of % by weight of total fatty acids.
Plasma leptin levels were measured by an enzyme-
linked immunosorbent assay (ELISA) kit (Millipore, MA, 
USA), according to the manufacturers’ instructions with a 
sensitivity of 0.78 ng/mL – 100 ng/mL. None of the samples 
was under the detection limit of the ELISA kit.
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Statistical analysis
Statistical analyses were performed using Statistical SPSS 
software (version 13.0; SPSS Inc., IL, USA). According to 
the distribution of data whether normally distributed or not, 
the differences between the means/medians belonging to 
two groups were analyzed by the appropriate statistical tests 
such as Unpaired t test/Mann Whitney U test. The data were 
presented as mean ± standard deviation (SD) or median, 
range. Nonparametric Spearman’s correlation coefficient 
was used to find any correlation between leptin level in cord 
blood and the other parameters. A P value of <0.05 was 
considered statistically significant.
Results
Anthropometric parameters
The anthropometric parameters of the mothers and babies 
are shown in Table I. There were no statistical differences 
between both groups according to mother age, number 
of previous pregnancies, BMIs of the mothers before 
pregnancy, maternal body weight gain during pregnancy 
and gestational age at delivery.
Medians of z scores for weight, height and head 
circumference of the newborns in the supplemented group 
were lower then the levels in the control group. But, these 
were not statistically significant.
Fatty acid compositions of cord blood
In Table II, we depicted the mean ± SD for fatty 
acid concentrations in umbilical cord plasma. The 
supplementation induced some significant changes in fatty 
acid levels of cord bloods.
As expected before, the supplementation significantly 
increased EPA and DHA levels in the cord bloods of the 
supplemented group. Simultaneously, total amount of n-3 
PUFAs was significantly higher after treatment.
On the other hand, we observed that the amounts of 
the members of n-6 PUFAs family were decreased with 
the supplementation except linoleic acid (LA, C18:2-n6). 
LA increased in the cord bloods of the supplemented 
group when compared to the levels in the control group. In 
addition, n-6/n-3 PUFAs ratios in cord bloods were lower in 
mothers who received the supplement than the ratios in the 
control group (P=0.052).
Moreover, the mean levels of total saturated fatty acids 
(SFAs) and total monounsaturated fatty acids (MUFAs) 
remained unchanged, while total PUFAs were slightly, but 
not considerably, higher in mothers who took the supplement 
than those in mothers of the control group.
Leptin levels and correlations with other parameters
The mean leptin levels in cord bloods were 8.5 ± 5.8 ng/mL 
in the control group and 5.7 ± 3.9 ng/mL in the supplemented 
Table I. Effects of the EPA/DHA supplementation on anthropometric parameters of the mothers and newborns
CONTROL  
GROUP
(mean ± SD)
SUPPLEMENTED GROUP
(mean ± SD) * P value
n 18 13
Maternal Age (years) 30.2 ± 3.8 32.3 ± 4.3 0.174
Number of previous pregnancies 1.5 ± 0.5 1.7 ± 0,6 0.289
BMIs of the mothers before pregnancy 22.8 ± 2.2 22.2 ± 2.5 0.479
Body weight gain of the mothers during pregnancy (kg) 15.1 ± 6.6 15.4 ± 4.7 0.865
Gestational age at delivery (days) 271.8 ± 7.7 272.1 ± 7.9 0.917
CONTROL  
GROUP
(median, range)
SUPPLEMENTED GROUP
(median, range) ** P value
n 13 11
z score for weight of newborn 0.57 ± 4.06 0.04 ± 1.74 0.999
z score for height of newborn 0.59 ± 4.12 0.46 ± 2.12 0.240
z score for head circumference of newborn 0.52 ± 4.58 0.42 ± 2.11 0.999
* Parametric test: Unpaired t test. ** Nonparametric test: Mann Withney U test. Significantly different from control, **P < 0.001, *P< 0.05. (BMI: body 
mass index; EPA: eicosapentanoic acid; DHA: docosahexaenoic acid; SD: standard deviation)
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group. It was decreased in the supplemented group without 
any statistical differences (P = 0.140).
As shown in Table III, with non-parametric Spearman 
correlation analysis of the data, we found no significant 
correlation between leptin concentrations and mother ages, 
number of previous pregnancies and maternal body weight 
gain during pregnancy in both groups.
There were nonsignificant negative correlation between 
leptin concentrations and BMIs of the mothers before 
pregnancy and nonsignificant positive correlation between 
leptin concentrations and gestational ages at delivery in 
both groups
An interesting finding was the positive correlation 
between leptin levels and the z scores for birth weight, 
height and head circumference of the newborns in the 
control group. But, the associations with z scores for 
birth height and head circumference changed to the 
nonsignificant negative correlations in the supplemented 
group (Table III).
There was a nonsignificant negative correlation between 
leptin concentrations and SFAs levels in both groups but 
this correlation was stronger in the supplemented group. 
Furthermore, we observed that the supplementation resulted 
in a nonsignificant negative correlation between leptin 
concentrations and the total n-3 PUFAs concentrations. But 
there were no correlations between leptin concentrations and 
the total n-6 PUFAs concentrations in both groups. On the 
other hand, the supplementation made leptin concentrations 
in the cord blood positively correlated with n-6/n-3 PUFA 
ratio. But, these correlations failed to be statistically 
significant (Table IV).
Table II. Comparison of fatty acid composition (percentage by weight of total identified fatty acids; wt %) of cord bloods in the control 
and supplemented group.
FATTY ACID
CONTROL GROUP
(mean ± SD)
SUPPLEMENTED GROUP
(mean ± SD) P value
n 18 13
C 14:0 0.78 ± 0.35 0.77 ± 0.32 0.938
C 15:0 0.19 ± 0.05 0.20 ± 0.04 0.651
C 16:0 32.74 ± 1.18 33.00 ± 1.27 0.563
C 17:0 0.25 ± 0.05 0.27 ± 0.07 0.421
C 18:0 12.29 ± 1.21 11.59 ± 1.27 0.127
C 20:0 0.28 ± 0.11 0.23 ± 0.11 0.211
C 22:0 0.22 ± 0.08 0.19 ± 0.08 0.260
Total SFAs 46.77 ± 1.96 46.30 ± 1.29 0.451
C 16:1 3.34 ± 0.67 3.31 ± 1.10 0.912
C 17:1 0.16 ± 0.05 0.11 ± 0.04 0.005
C 18:1 17.81 ± 1.87 17.59 ± 1.68 0.729
C 20:1n9 0.07 ± 0.02 0.1 ± 0.06 0.434
C 24:1 0.25 ± 0.13 0.20 ± 0.30 0.577
Total MUFAs 21.57 ± 2.38 21.22 ± 2.13 0.668
C 18:2n6 (LA) 10.83 ± 2.04 12.76 ± 3.37 0.056
C 18:3n6 0.30 ± 0.09 0.20 ± 0.11 0.009
C 18:3n3 0.13 ± 0.15 0.16 ± 0.09 0.641
C 18:4n3 0.07 ± 0.04 0.10 ± 0.03 0.226
C 20:2n6 0.66 ± 0.20 0.50 ± 0.31 0.090
C 20:3n6 3.11 ± 0.77 2.26 ± 0.93 0.009
C 20:4n6 12.98 ± 1.39 12.65 ± 2.10 0.608
C 20:5n3 (EPA) 0.08 ± 0.03 0.15 ± 0.08 0.021
C 22:4n6 0.37 ± 0.10 0.26 ± 0.08 0.003
C 22:5n6 0.58 ± 0.21 0.36 ± 0.17 0.004
C 22:5n3 0.09 ± 0.05 0.15 ± 0.07 0.026
C 22:6n3 (DHA) 2.57 ± 0.66 3.17 ± 0.91 0.043
Total PUFAs 31.66 ± 1.75 32.50 ± 2.26 0.255
Total n-3 PUFAs 2.85 ± 0.68 3.52 ± 0.98 0.032
Total n-6 PUFAs 28.82 ± 1.99 28.99 ± 2.36 0.830
n-6/n-3 PUFAs ratio 10.68 ± 2.65 8.82 ± 2.34 0.052
(SFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; LA: linoleic acid; EPA: eicosapentaenoic acid; 
DHA: docosahexaenoic acid; SD: standard deviation)
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Table III. Association of leptin concentrations in cord bloods with anthropometric parameters of the mothers and newborns in the control 
and supplemented group.
LEPTIN CONCENTRATIONS IN CORD BLOOD
CONTROL MOTHERS SUPPLEMENTED MOTHERS
Spearman’s correlation 
coefficient
P value
Spearman’s correlation 
coefficient
P value
Maternal Age (years) -0.423 0.071 0.476 0.118
Number of previous pregnancies -0.212 0.384 0.420 0.153
BMIs of the mothers before pregnancy -0.253 0.311 -0.406 0.191
Body weight gain of the mother during 
pregnancy
0.110 0.664 0.213 0.485
Gestational age at delivery (days) 0.252 0.312 0.523 0.067
z score for weight of newborn 0.523 0.067 0.245 0.467
z score for height of newborn 0.581 0.037 -0.240 0.478
z score for head circumference of newborn 0.590 0.034 -0.410 0.273
Table IV. The correlation between each fatty acid concentration (percentage by weight of total identified fatty acids; wt %) and leptin 
concentration in the cord bloods of both groups.
LEPTIN CONCENTRATIONS IN CORD BLOOD
CONTROL MOTHERS SUPPLEMENTED MOTHERS
FATTY ACID
Spearman’s correlation 
coefficient
P value
Spearman’s correlation 
coefficient
P value
C 14:0 -0.034 0.893 -0.410 0.164
C 15:0 0.098 0.700 -0.490 0.089
C 16:0 0.053 0.836 -0.363 0.223
C 17:0 -0.082 0.746 -0.055 0.858
C 18:0 -0.395 0.104 -0.159 0.603
C 20:0 0.093 0.713 -0.096 0.754
C 22:0 -0.176 0.484 -0.259 0.393
Total SFAs -0.200 0.425 -0.522 0.067
C 16:1 0.474 0.047 0.451 0.122
C 17:1 0.039 0.876 -0.400 0.176
C 18:1 0.176 0.484 0.401 0.174
C 24:1 -0.056 0.826 -0.047 0.880
Total MUFAs 0.267 0.284 0.522 0.067
C 18:2n6 (LA) -0.199 0.428 -0.236 0.437
C 18:3n6 0.041 0.869 0.039 0.900
C 18:3n3 0.019 0.950 0.107 0.819
C 18:4n3 0.289 0.487 0.308 0.614
C 20:2n6 0.377 0.123 0.198 0.517
C 20:3n6 0.311 0.210 0.099 0.748
C 20:4 -0.174 0.489 0.154 0.616
C 20:5n3 (EPA) 0.296 0.248 -0.489 0.107
C 22:4n6 0.075 0.769 0.168 0.583
C 22:5n6 0.025 0.922 0.287 0.343
C 22:5n3 0.308 0.264 0.228 0.588
C 22:6n3 (DHA) -0.137 0.587 -0.308 0.306
Total PUFAs -0.174 0.489 -0.132 0.668
Total n-3 PUFAs 0.082 0.748 -0.385 0.194
Total n-6 PUFAs -0.183 0.468 -0.088 0.775
n-6 / n-3 PUFAs ratio -0.080 0.754 0.379 0.201
(SFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; LA: linoleic acid; EPA: eicosapentaenoic acid; 
DHA: docosahexaenoic acid)
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Discussion
The nutritional factors, which affect the baby health during 
pregnancy, determine the risk for diseases or prevention 
from diseases in postnatal life [11]. n-3 LC-PUFAs have 
positive impact on fetal development. Several studies 
showed beneficial effects of higher intake of n-3 FAs, 
particulary DHA and EPA, on neuronal, retinal, and immune 
function of infants [12]. On the other hand, some studies 
failed to show same effects [13]. Intake of n-3 LC-PUFAs 
during pregnancy also plays an important role on pregnancy 
outcomes in a good way. It was shown that n-3 LC PUFAs 
consumption during pregnancy resulted in longer gestation 
time, increase in head circumference of newborn, higher 
birthweight and lower risk of early preterm birth [1, 14-
15]. However, there are some studies, which could not 
demonstrate these correlations [14, 16-17]. We believe that, 
these differences might depend on different concentrations 
of n-3 LC-PUFAs used in these studies. Especially, the last 
trimester of pregnancy is a critical period for requirement 
of n-3 PUFAs for the fetus [18]. In the current study, we 
observed a tendency for a reduction in the medians of z 
scores for weight, height and head circumference of the 
newborns whose mothers daily took a supplementation 
of n-3 LC-PUFAs during last trimester of their gestation, 
however, the results were not statistically significant. In 
the meantime, there were no changes in gestational age at 
delivery between the supplemented and the control groups.
Because fetus is limited in their ability to make n-3 LC-
PUFAs, n-3 LC-PUFAs in mother’s diet are the main source 
for fetus and the transportation of them through placenta is 
essential [1]. It was observed that enhanced maternal dietary 
intake of DHA+EPA increased DHA concentrations in cord 
blood [19]. In our study, we found that intake of n-3 LC-
PUFAs during last trimester affected fatty acid composition 
in cord blood and resulted in rising total n-3 PUFAs and LA.
It is known that high n-6/n-3 PUFAs ratio in maternal diet 
is negatively associated with development of infants [20]. 
Because both n-3 and n-6 PUFAs are substrates for the same 
enzymes, they show an inhibitory effect on the synthesis of 
each other. So, n-6/n-3 PUFA ratio is more important than 
the levels of n-3 or n-6 PUFAs individually. Even if the 
ideal n-6/n-3 PUFAs ratio in diet is 5:1, it increases to 10:1 
-20:1 in industrialized countries [21]. In the current study, 
we observed that intake of EPA and DHA in last trimester 
resulted in a decrease n-6 /n-3 ratio in the cord blood.
Leptin, as a potent stimulator of lipolysis, is one of the 
key factors, which regulates mobilization of PUFAs from 
maternal adipose tissue into placenta. It is mainly produced 
by maternal and fetus adipose tissues and also placenta 
in prenatal life [5]. Placenta-derived leptin modulates 
transportation of PUFAs via placenta in response to the 
fetal demand [3]. Placenta has leptin receptors and through 
these receptors, maternal leptin is taken by placenta and 
fetus [22]. The binding of leptin to its receptors on placenta 
is regulated by maternal fatty acids. It was observed that 
increase n-3 PUFA intake by mother rats decreased leptin 
levels in suckling pups’ serum [23]. In the meanwhile, it 
was shown that EPA and DHA decreased uptake of leptin by 
human placental choriocarcinoma cells while arachidonic 
acid stimulated it invitro [24]. In our study, we showed that 
intake of n-3 PUFAs during last trimester of pregnancy 
seemed to cause a decrease in leptin concentration of cord 
blood but it was not statistically significant. Furthermore, 
higher total n-3 PUFAs levels were associated with lower 
leptin concentrations in cord plasma in the supplemented 
group but P value was found statistically nonsignificant. On 
the other hand, there was no correlation at all in the control 
group.
It is belived that the ratio of n-6/n-3 PUFA in the maternal 
diet is more important for affecting serum leptin levels than 
individual levels of n-6 or n-3 LC-PUFAs. It was shown that 
higher n-6/n-3 PUFAs ratio in maternal diet increased serum 
leptin levels of rat pups [23]. Consistent with this data we 
observed a nonsignificant positive correlation between 
n-6/n-3 PUFAs ratio and leptin levels in cord bloods of the 
supplemented group. On the other hand, it was found in an 
other study that reduced n-6/n-3 PUFA ratio in maternal diet 
did not affect leptin levels in maternal or cord blood [10].
Beside the roles of leptin in many physiological 
processes, its roles in perinatal period have been studied in 
a few studies. Leptin might be involved in the process of 
placentation. It was observed that leptin levels in maternal 
plasma and leptin protein levels in placenta were higher in 
pre-eclamptic pregnants than in controls at delivery [25]. 
Additionally, leptin was significantly lower in mothers 
who delivered preterm vs term babies [26]. Some studies 
showed that cord blood leptin levels were positively 
correlated with maternal BMI, neonatal adiposity, fetal 
growth indeces and placental weight [7,27,28]. In this study, 
we observed a positive correlation between leptin levels in 
cord blood and newborn health outcomes (weight, height 
and head circumference z scores) in the control group. But 
interestingly this correlation was turned into negative and 
nonsignificant correlation in the supplemented group. We 
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argue that the results until today are not enough to conclude 
leptin is a determinant of fetal growth.
These studies prove that ideal level of leptin in maternal 
circulation and cord blood is important for baby and mother 
health. The mean cord blood leptin concentration in this 
study were ~ 8.5 ng/mL in the control group which was 
in agreement with levels in other studies [29,30]. One of 
the factors that affect the leptin levels in prenatal life is 
neonatal and mother fat mass [8]. This may explain our 
data that leptin levels in cord blood were positively but 
nonsignificantly correlated with maternal body weight gain 
during pregnancy.
The main limitation of this study is the relatively small 
sample size. Low statistical power of the results and the 
correlations are most likely related with this limitation.
In conclusion, our findings suggest that maternal intake 
of n-3 LC-PUFAs during pregnancy might play a role in 
lipid profile and leptin signal during prenatal development. 
Our data can help researchers to shape new prospective 
studies with larger populations and for longer periods.
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